When experience builds to evidence: Peer-reviewed real-world evidence analysis

Data from clinical trials has demonstrated the prognostic value of MRD within controlled research settings, do those findings hold true in routine clinical practice? clonoSEQ is used to assess MRD at all 30 NCCN® Member Institutions and clinicians are increasingly publishing evidence of the prognostic value of MRD testing in the real world.

This page is intended for use by healthcare professionals of the United States.

clonoSEQ® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technicalsummary.

Test Your clonoSEQ Knowledge

How much do you know about clonoSEQ MRD testing in clinical practice?

clonoSEQ MRD Quiz